Author Affiliations: Institute of Clinical Medicine and University of Helsinki and Department of Dermatology, Allergology, and Venereology, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.
I read with great interest the article by Guenova et al,1 who showed a biological “proof of concept” with an increase expression of interleukin (IL)-23 in a pyoderma gangrenosum (PG) lesion before initiating ustekinumab therapy successfully. A wide number of local and systemic treatments have been tried for this difficult condition and, in the era of biological agents, new, targeted therapies are promising.2
Kluger N. Ustekinumab for Pyoderma Gangrenosum. Arch Dermatol. 2012;148(5):655. doi:10.1001/archdermatol.2012.78